Natural history of progression after PSA elevation following radical prostatectomy.
暂无分享,去创建一个
A W Partin | D. Chan | A. Partin | P. Walsh | M. Eisenberger | J. Pearson | C. Pound | D W Chan | P C Walsh | C R Pound | J D Pearson | M A Eisenberger | Daniel W. Chan
[1] P. Walsh. BENIGN AND MALIGNANT NEOPLASMS OF PROSTATE , 2000 .
[2] I. Thompson,et al. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. , 1998, The New England journal of medicine.
[3] R. Veltri,et al. The role of biopsy pathology, quantitative nuclear morphometry, and biomarkers in the preoperative prediction of prostate cancer staging and prognosis. , 1998, Seminars in urologic oncology.
[4] J. Dekernion,et al. Recurrence patterns after radical retropubic prostatectomy: clinical usefulness of prostate specific antigen doubling times and log slope prostate specific antigen. , 1997, The Journal of urology.
[5] H. Lai,et al. Survival after radical prostatectomy. , 1997, JAMA.
[6] M. Kattan,et al. Hazard rates for progression after radical prostatectomy for clinically localized prostate cancer. , 1997, Urology.
[7] A. Partin,et al. Prostate-specific antigen after anatomic radical retropubic prostatectomy. Patterns of recurrence and cancer control. , 1997, The Urologic clinics of North America.
[8] J. Moul,et al. Biostatistical modeling using traditional variables and genetic biomarkers for predicting the risk of prostate carcinoma recurrence after radical prostatectomy , 1997, Cancer.
[9] P. Schellhammer,et al. Results of radical prostatectomy in men with clinically localized prostate cancer. , 1996, JAMA.
[10] F. Marshall,et al. Selection of men at high risk for disease recurrence for experimental adjuvant therapy following radical prostatectomy. , 1995, Urology.
[11] W. Catalona,et al. 5-year tumor recurrence rates after anatomical radical retropubic prostatectomy for prostate cancer. , 1994, The Journal of urology.
[12] J. Oesterling,et al. Long-term (15 years) results after radical prostatectomy for clinically localized (stage T2c or lower) prostate cancer. , 1994, The Journal of urology.
[13] R. B. Smith,et al. The incidence and significance of detectable levels of serum prostate specific antigen after radical prostatectomy. , 1994, The Journal of urology.
[14] P. Scardino,et al. Can radical prostatectomy alter the progression of poorly differentiated prostate cancer? , 1994, The Journal of urology.
[15] P. Walsh,et al. Prognostic factors in men with stage D1 prostate cancer: identification of patients less likely to have prolonged survival after radical prostatectomy. , 1994, The Journal of urology.
[16] A. Partin,et al. Evaluation of serum prostate-specific antigen velocity after radical prostatectomy to distinguish local recurrence from distant metastases. , 1994, Urology.
[17] J. Adolfsson,et al. RECENT RESULTS OF MANAGEMENT OF PALPABLE CLINICALLY LOCALIZED PROSTATE CANCER. AUTHORS' REPLY , 1994 .
[18] A W Partin,et al. Serum PSA after anatomic radical prostatectomy. The Johns Hopkins experience after 10 years. , 1993, The Urologic clinics of North America.
[19] E. Bergstralh,et al. Stage D1 prostate cancer treated by radical prostatectomy and adjuvant hormonal treatment. Evidence for favorable survival in patients with DNA diploid tumors , 1992, Cancer.
[20] S. Larson,et al. Therapeutic alternatives for hormone-refractory prostatic cancer. , 1992, Seminars in urology.
[21] M. Soloway. The Importance of Prognostic Factors in Advanced Prostate Cancer , 1990, Cancer.
[22] M. Soloway,et al. Clinical study of leuprolide depot formulation in the treatment of advanced prostate cancer. The Leuprolide Study Group. , 1990, The Journal of urology.
[23] P. Goodman,et al. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. , 1989, The New England journal of medicine.
[24] R. Gibbons,et al. Total prostatectomy for clinically localized prostatic cancer: long-term results. , 1989, The Journal of urology.
[25] K. Griffiths,et al. Endocrine treatment of prostate cancer. , 1989, Progress in medicinal chemistry.
[26] P. Walsh,et al. Cause-specific actuarial survival analysis: a useful method for reporting survival data in men with clinically localized carcinoma of the prostate. , 1989, The Journal of urology.
[27] D. Byar,et al. Hormone therapy for prostate cancer: results of the Veterans Administration Cooperative Urological Research Group studies. , 1989, NCI monographs : a publication of the National Cancer Institute.
[28] E. Kramolowsky. The value of testosterone deprivation in stage D1 carcinoma of the prostate. , 1988, The Journal of urology.
[29] S. Al-Askari,et al. Radical prostatectomy for stage D1 prostate cancer , 1987 .
[30] D. Byar. The veterans administration cooperative urological research group's studies of cancer of the prostate , 1973, Cancer.
[31] E. Kaplan,et al. Nonparametric Estimation from Incomplete Observations , 1958 .
[32] W. Isaacs,et al. The Prostate , 2019 .